Montelukast nasal spray: formulation development and in vitro evaluation.


Journal

Pharmaceutical development and technology
ISSN: 1097-9867
Titre abrégé: Pharm Dev Technol
Pays: England
ID NLM: 9610932

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 21 8 2018
medline: 16 4 2019
entrez: 21 8 2018
Statut: ppublish

Résumé

The aim of this study was to evaluate potential development of montelukast sodium (MTS) as a nasal spray. The formulations were prepared using hydroxypropyl cellulose (HPC) and carbomer 940 (C940). The prepared formulations were evaluated for clarity, pH, hydrodynamic size, zeta potential, viscosity, contact angle, surface tension, droplet size distribution, muco-adhesiveness, drug release, and stability. The suitable formulations were also assessed for their effects on nasal epithelial cells. At room temperature (25 °C), the formulation containing 0.01% w/v C940 exhibited suitable viscosity and rheological properties. Spray droplets were in ranges of 10-40 µm, which are suitable for nasal administration. The works of adhesion of the formulations containing HPC or C940 were in the range of 0.8-4.0 and 0.2-27 µJ, respectively. In addition, the formulation containing 0.01% w/v C940 and the 0.5-15 µg/50 µL concentrations of MTS showed no signs of cytotoxicity and did not open the tight junction of nasal epithelial cells. The formulated MTS nasal spray is ideal for nasal administration for the treatment of allergic rhinitis. The formulation containing 0.01% w/v C940 had no toxicity nor alteration on the tight junction of nasal epithelial cells.

Identifiants

pubmed: 30124348
doi: 10.1080/10837450.2018.1514523
doi:

Substances chimiques

Acetates 0
Anti-Asthmatic Agents 0
Cyclopropanes 0
Nasal Sprays 0
Quinolines 0
Sulfides 0
montelukast MHM278SD3E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

494-503

Auteurs

Thunyaporn Jullaphant (T)

a Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai , Songkhla , Thailand.

Titpawan Nakpeng (T)

b Nanotec-PSU Excellence Center on Drug Delivery System, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai , Songkhla , Thailand.

Teerapol Srichana (T)

a Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai , Songkhla , Thailand.
b Nanotec-PSU Excellence Center on Drug Delivery System, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai , Songkhla , Thailand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH